A recent trial conducted by Japanese scientists has revealed that daily vitamin D supplements do not seem to prevent the development of type 2 diabetes in people already at high risk of the condition. The findings of the trial were published in The BMJ on Thursday.
According to the trial results, the supplements had no clinically meaningful effect in high-risk adults. However, it suggests there may be a benefit for people with insufficient insulin secretion, although this finding remains unclear.
Around 480 million people are affected with Type 2 diabetes worldwide and are predicted to increase to 700 million by 2045. Another half a billion people have impaired glucose tolerance or pre-diabetes. According to experts, Weight loss and exercise can lower the risk of progression to type 2 diabetes, but are difficult to sustain, so new strategies are needed to tackle the problem. Previous studies have shown that vitamin D deficiency is associated with an increased risk of future diabetes, but trials of vitamin D supplements for preventing type 2 diabetes show inconsistent results.
The researchers set out to assess whether eldecalcitol, which is an active form of vitamin D used to treat osteoporosis in Japan, could reduce the risk of developing type 2 diabetes among people with impaired glucose tolerance. Their findings are based on 1,256 Japanese adults with impaired glucose tolerance recruited from three hospitals in Japan between June 2013 and August 2019. Their average age was 61 (range 30-78) years, 46% were women, and 59% had a family history of type 2 diabetes.
While conducting the trial, the researchers found no meaningful differences between groups in those who developed diabetes (12.5% in the eldecalcitol group and 14% in the placebo group) or whose blood sugar levels returned to normal (23% in the eldecalcitol group and 20% in the placebo group). However, after adjusting for 11 potentially influential factors, including age, sex, blood pressure, body mass index, and family history of diabetes, the results suggested that eldecalcitol might prevent type 2 diabetes in pre-diabetic patients with insufficient insulin secretion. But this finding remains unclear and the researchers say further work is needed before any firm conclusions can be made.
They did, however, find a significant increase in both lower back and hip bone mineral densities among those taking eldecalcitol compared with placebo. However, no significant difference in serious adverse events was seen between the two groups.
The researchers acknowledge some uncertainties, such as whether the dose of eldecalcitol used was appropriate for preventing diabetes, and whether the results apply to all ethnicities. Nevertheless, this was a large trial with regular follow-up and high adherence to treatment, suggesting that the findings are robust.
This new trial was well conducted and results are consistent with two other recent trials, says Tatiana Christides at Queen Mary University of London in a linked editorial.
Until further data are available from high-quality randomised trials, she suggests healthcare professionals “should continue to discuss with patients the musculoskeletal health benefits of vitamin D and support them to achieve and maintain lifestyle changes that, although challenging to sustain, are known to decrease the development of type 2 diabetes.”